Send to

Choose Destination
Lancet HIV. 2015 Aug;2(8):e319-27. doi: 10.1016/S2352-3018(15)00114-9. Epub 2015 Jul 9.

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.

Author information

Bonn University Hospital, Bonn, Germany. Electronic address:
Chelsea and Westminster Hospital, London, UK.
Sorbonne Universities, UPMC University of Paris 06, INSERM UMR_S 1136, Pierre Louis Institute of Epidemiology and Public Health, Paris, France; APHP Pitié-Salpêtrière Hospital, Paris, France.
Quest Clinical Research, San Francisco, CA, USA.
Hospital Clinic-University of Barcelona, Barcelona, Spain.
Holdsworth House Medical Practice, Darlinghurst, NSW, Australia.
St Vincent's Hospital, Sydney, NSW, Australia.
University of Alabama at Birmingham, Birmingham, AL, USA.
Division of Hepatology, Carolinas Medical Center, Charlotte, NC, USA.
Royal London Hospital, Bart's Health NHS Trust, London, UK.
Merck & Co, Inc, Kenilworth, NJ, USA.
Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Erratum in

  • Lancet HIV. 2015 Aug;2(8):e316.
  • Lancet HIV. 2015 Oct;2(10):e416.



Hepatitis C virus (HCV) infection is a leading cause of morbidity and mortality in patients with HIV-1. The C-EDGE CO-INFECTION study assessed the efficacy, safety, and tolerability of grazoprevir (MK-5172) plus elbasvir (MK-8742) in patients with HCV and HIV co-infection.


In this uncontrolled, non-randomised, phase 3, open-label, single-arm study, treatment-naive patients with chronic HCV genotype 1, 4, or 6 infection and HIV co-infection, with or without cirrhosis, were enrolled from 37 centres in nine countries across Europe, the USA, and Australia. Patients were either naive to treatment with any antiretroviral therapy (ART) or stable on ART for at least 8 weeks. All patients received grazoprevir 100 mg plus elbasvir 50 mg in a fixed-dose combination tablet once daily for 12 weeks. The primary endpoint was sustained virological response (HCV RNA <15 IU/mL) 12 weeks after the end of therapy (SVR12). The primary population for efficacy analyses was all patients who received at least one dose of study treatment. This study is registered with, number NCT02105662.


Between June 11, 2014, and Aug 29, 2014, 218 patients were enrolled and received grazoprevir plus elbasvir for 12 weeks, all of whom completed follow-up at week 12. SVR12 was achieved by 210 (96%) of 218 patients (95% CI 92·9-98·4). One patient did not achieve SVR12 because of a non-virological reason, and seven patients without cirrhosis relapsed (two subsequently confirmed as reinfections). All 35 patients with cirrhosis achieved SVR12. The most common adverse events were fatigue (29; 13%), headache (27; 12%), and nausea (20; 9%). No patient discontinued treatment because of an adverse event. Two patients receiving ART had transient HIV viraemia.


This HCV treatment regimen seems to be effective and well tolerated for patients co-infected with HIV with or without cirrhosis. These data are consistent with previous trials of this regimen in the monoinfected population. This regimen continues to be studied in phase 3 trials.


Merck Sharp & Dohme Corp.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center